Salarius Pharmaceuticals (NASDAQ:SLRX) CEO David Arthur sat down with Proactive at the Biotech Showcase 2020 in San Francisco. The Texas-based oncology company's lead candidate, Seclidemstat, is currently in clinical development to treat Ewing sarcoma. Seclidemstat has been granted Orphan Drug designation and Pediatric Rare Disease Designation by the FDA.
Salarius Pharmaceuticals CEO talks through recent achievements for its lead cancer drug candidate
Quick facts: Salarius Pharmaceuticals
Price: 0.8205 USD
Market Cap: $10.56 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE